glp-1 agonist cardiovascular outcomes in major trials with receptor agonists GLP-1 Agonists in Cardiovascular Diseases:
Description
While initial effects at 3 months were minimal, sustained reductions at later time points suggest a potentially durable effect on BMI (Figure 2)
During this period, there are no specified limits on the volume of clear fluids that can be consumed
[DOI] [PubMed] [Google Scholar] 43.Frias JP, et al
61 A large observational study in Sweden similarly found that semaglutide and liraglutide use were associated with a lower risk of hospitalization due to alcohol use disorder (aHR for semaglutide: 0.64, 95% CI 0.50, 0.83
For a 5 mg/mL concentration: add 2 mL of water
